Olink
- Company typePrivate
- Founded2004
- HeadquartersUppsala, Sweden
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Olink firmographics
Firmographics- Name
- Olink
- Legal name
- Olink Proteomics AB
- Website
- https://olink.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Ownership category
- akta.pro rank
Olink industry classification
Industry- Product category
- Proteomics Research Tools
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Proteomics & Biomarker Analytical Testing (HLAGADAG)
- akta.pro secondary industries
- Proteomics & Mass Spectrometry Services (HLAGANAB), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Translational Medicine & Biomarkers (HLAIALAF), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Olink is headquartered
LocationHeadquarters
- HQ city
- Uppsala
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Olink business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- Proteomics Instruments: Sale of Olink Signature Q100 instruments and related hardware to research institutions and pharmaceutical companies for in-house proteomics capabilities.
- Assay Kits and Reagents: Recurring revenue from sale of PEA-based assay kits including Explore, Target, Flex, and Focus product lines. Kits contain antibody pairs, detection reagents, and consumables for specific protein biomarker panels.
- Analysis Services: Olink operates certified service provider network and offers direct analysis services for customers who prefer outsourced proteomics testing rather than running assays in-house.
- Data Science Services: Consulting and bioinformatics services to help customers design studies, analyze proteomics data, and generate insights from biomarker discoveries.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise/Bulk licensing available for pharmaceutical and biotech customers |
| Unit Pricing | Pay-as-you-go | Individual assay kit pricing for academic and smaller research labs |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
Olink product offering
Product offeringCore offering
Olink develops and sells proprietary proteomics instruments, multiplex assay kits, and bioinformatics software built on its patented Proximity Extension Assay (PEA) technology for high-throughput protein biomarker analysis. Its product lines include the Olink Explore HT discovery platform, Olink Reveal NGS-based platform, Olink Target 96/48 targeted panels, Olink Flex and Focus custom kits, and the Olink Signature Q100 automated instrument, complemented by Olink Insight/Analyze/NPX software and outsourced Analysis and Data Science Services. Customers are pharmaceutical and biotechnology companies, academic research institutions, and clinical research organizations using these tools for biomarker discovery, drug target identification, patient stratification, and clinical trial research.
Product overview
Olink is a next-generation proteomics company (now part of Thermo Fisher Scientific) offering a platform-plus-products architecture based on its proprietary Proximity Extension Assay (PEA) technology. The portfolio centers on Olink Explore HT as the flagship high-throughput discovery platform, complemented by the modular Olink Explore 3072/384 (being discontinued in 2026) and Olink Reveal for NGS-based proteomics. The Olink Target series provides hypothesis-driven targeted proteomics with Olink Target 96 (11 panels, 88 proteins each), Olink Target 48 (Cytokine and Immune Surveillance panels), Olink Target 48 Neurodegeneration, and Olink Target 48 Mouse. Supporting offerings include Olink Flex and Olink Focus for flexible/focused applications, Olink Concordance Test for quality control, and the Olink Signature Q100 instrument. Software includes Olink Insight (bioinformatics), Olink Analyze, and NPX Software for data analysis. Services encompass Olink Analysis Services and Olink Data Science Services. Olink also fosters research collaboration through consortia including SCALLOP (proteogenomics), CORAL (neurology), and COLLIBRI (IBD). The company reports over 4,000 peer-reviewed publications demonstrating platform utility across cardiovascular, immunology, oncology, neurology, and metabolic disease research.
Differentiator
Problem solved
Functional benefit
Brands
- Olink Explore: High-throughput proteomics platform for hypothesis-driven biomarker discovery
- Olink Target
- Olink Reveal
- Olink Flex
- Olink Focus
- Olink Signature Q100
- Olink Insight
- Olink Analyze
- NPX Software
- Olink Shield
Products and services
- Olink Explore HT Next-generation high-throughput proteomics platform for discovery-scale protein biomarker analysis, measuring over 5,400 protein biomarkers from small blood samples (1 µL) using PEA technology with NGS readout, for population-scale proteogenomics studies by pharma, biotech, and academic customers.
- Olink Reveal
Quantifiable outcome
- Over 5,400 protein biomarkers measurable from small sample volumes
- +3 more outcomes
Companies that use Olink
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Olink technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Olink partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and strategic.
- CORAL ConsortiumcoreCORAL (Community using Olink for Research on Alzheimer's Disease and other neurological diseases) is a collaborative framework dedicated to accelerating identification of proteins and mechanisms for neurological diseases and translation of novel biomarkers to clinic. Includes research on Alzheimer's, Parkinson's, FTD, MS, ALS, and other neurological conditions.
- UK BiobankcoreLandmark partnership for population-scale proteogenomics research. UK Biobank is utilizing Olink's PEA technology for their ambitious proteomics program analyzing hundreds of thousands of participants, resulting in multiple high-impact Nature publications demonstrating the power of discovery-scale proteomics integrated with genomic data.
- SCALLOP ConsortiumcoreSCALLOP (Systematic and Combined AnaLysis of Olink Proteins) is a collaborative consortium comprising numerous PIs from various research institutions contributing summary-level data from over 70,000 patients and controls across 45+ cohort studies. Focuses on discovering and following up on genetic associations with proteins on Olink's PEA platform.
- COLLIBRI ConsortiumcoreCOLLIBRI is a consortium aimed at accelerating progress in inflammatory bowel disease research through protein biomarkers. Engages both academic and industrial partners to share clinical samples and data, generating novel insights into disease pathogenesis and biomarker signatures at proteomic level.
- Strand Life Sciences (Reliance Industries)strategicStrand Life Sciences, a Reliance Industries subsidiary, has launched advanced proteomics capabilities enabled by the Olink Explore HT platform, enabling measurement of over 5,400 protein biomarkers from small blood samples for integrated multi-omics research and drug discovery in India and South Asia.
- Thermo Fisher ScientificcoreThermo Fisher Scientific completed acquisition of Olink in July 2024 for approximately $3.1 billion. Olink operates as a business unit within Thermo Fisher, combining its proteomics capabilities with Thermo Fisher's existing life sciences tools portfolio including mass spectrometry, CRO/CDMO services, and AI-enabled data platforms.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Olink competitors and assessment
Company assessmentDirect peers
- Meso Scale Diagnostics: Provides multiplex immunoassay platforms (Meso Scale Discovery / MSD) for protein biomarker analysis. Competes with Olink Target panels in pharma and clinical research for sensitive, high-throughput protein measurement.
- Quanterix: Single-molecule array (Simoa) technology for ultra-sensitive protein detection. Competes with Olink in neurology and biomarker discovery, particularly where detection of low-abundance proteins is required.
- SomaLogic (now Standard BioTools): Direct competitor in high-plex protein biomarker discovery using its SomaScan platform (aptamer-based). Now part of Standard BioTools, the merged entity competes directly with Olink's PEA technology across pharma and academic accounts.
Broad incumbents
- 10x Genomics: Single-cell and spatial genomics platforms with growing proteomics and multi-omics capabilities. Overlaps with Olink in translational research and population-scale biology applications.
- Bio-Rad Laboratories: Diversified life sciences tools company with protein analysis offerings including Bio-Plex multiplex assays. Competes broadly with Olink in proteomics workflows and serves overlapping pharma and academic customers.
- Thermo Fisher Scientific: Olink's parent company and the largest life sciences tools provider, offering Orbitrap mass spectrometry for proteomics and PPD CRO services. Internal overlap creates both synergy and channel conflict considerations.
- Bruker: Mass spectrometry and proteomics instrumentation provider (timsTOF, timsMetabo). Competes with Olink's protein biomarker workflows in discovery proteomics and pharma applications.
Emerging players
- Cytek Biosciences: Flow cytometry and cell analysis company expanding into high-parameter immune profiling. Adjacent to Olink's immunology and immuno-oncology panels, particularly in translational and clinical research settings.
- Seer: Proteomics platform leveraging nanoparticle-based enrichment for deep, unbiased proteome analysis. Competes with Olink Explore in discovery-scale proteomics applications.
- Nautilus Biotechnology: Emerging proteomics platform using single-molecule analysis to characterize the full proteome. Represents a potential long-term disruptor to Olink's targeted/affinity-based multiplexing approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Olink social profiles
Digital presenceOlink financial estimates
Financial estimateRevenue estimate
Valuation estimate
Olink leadership team
Management profileNumber of profiles
Profiles2 records
Olink funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Olink M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Olink
What does Olink do?
Olink develops and sells proprietary proteomics instruments, multiplex assay kits, and bioinformatics software built on its patented Proximity Extension Assay (PEA) technology for high-throughput protein biomarker analysis. Its product lines include the Olink Explore HT discovery platform, Olink Reveal NGS-based platform, Olink Target 96/48 targeted panels, Olink Flex and Focus custom kits, and the Olink Signature Q100 automated instrument, complemented by Olink Insight/Analyze/NPX software and outsourced Analysis and Data Science Services. Customers are pharmaceutical and biotechnology companies, academic research institutions, and clinical research organizations using these tools for biomarker discovery, drug target identification, patient stratification, and clinical trial research.
Is Olink a public or private company?
Olink is a private company. It is classified as corporate owned and is currently operating.
When was Olink founded?
Olink was founded in 2004. It employs 501 to 1,000 people.
Where is Olink based?
Olink is headquartered in Uppsala, Sweden, in the Europe region.
How does Olink make money?
Four revenue lines are on record. Proteomics Instruments are the primary driver. The others are assay Kits and Reagents, analysis Services and data Science Services.
Who are Olink's main competitors?
Direct peers on record are Meso Scale Diagnostics, Quanterix and SomaLogic (now Standard BioTools). Broad incumbents are 10x Genomics, Bio-Rad Laboratories, Thermo Fisher Scientific and Bruker. Emerging players are Cytek Biosciences, Seer and Nautilus Biotechnology.
Does Olink have an API?
No public API is recorded for Olink.
What industry is Olink in?
Olink's product category is Proteomics Research Tools. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing, with a secondary code of HLAGANAB, Proteomics & Mass Spectrometry Services. Its NAICS code is 334516 and its SIC code is 3826.